Among women with osteoporosis randomized to discontinue bisphosphonates, results of bone mass testing in subsequent years were unrelated to future fracture risk. This undercuts guidelines and even a law.
(AAOS 2014) Older women with comorbidities are at greatest risk for revision surgery after total knee arthroplasty, a nationwide study shows. Another large analysis shows an interesting quirk about the role of osteoporosis: Bisphosphonates help, but only in some circumstances.
An expert working group says osteoporosis can be diagnosed in postmenopausal women and older men with only marginally low bone density, if they have fractured certain bones in a minor mishap, show vertebral fractures on X-ray, or have high fracture risk for other reasons.
How serious is the risk of atypical femur fracture for osteoporosis patients on bisphosphonates, and when is a "drug holiday" justified? There are no definitive studies or guidelines, but here are some strategies to consider.
New in the New England Journal: Romosozumab, whose target is sclerostin, increased BMD more than teriperatide and alendronate in a phase 2 trial involving postmenopausal women. Also, a puzzle: A rheumatic cause of abdominal pain.